BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34998597)

  • 21. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
    McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
    J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
    Shih IeM; Wang TL
    J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP Inhibitor Insensitivity to
    Sokol ES; Jin DX; Fine A; Trabucco SE; Maund S; Frampton G; Molinero L; Antonarakis ES
    JCO Precis Oncol; 2022 Jun; 6():e2100531. PubMed ID: 35772050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
    Siedel JH; Ring KL; Hu W; Dood RL; Wang Y; Baggerly K; Darcy KM; Conrads TP; Gallagher S; Tshiaba P; Neff C; Timms KM; Mangala S; Westin SN; Broaddus R; Lopez-Berestein G; Lu KH; Coleman RL; Maxwell GL; Sood AK
    Gynecol Oncol; 2021 Mar; 160(3):777-785. PubMed ID: 33563487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
    Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An integrated molecular profile of endometrioid ovarian cancer.
    Pierson WE; Peters PN; Chang MT; Chen LM; Quigley DA; Ashworth A; Chapman JS
    Gynecol Oncol; 2020 Apr; 157(1):55-61. PubMed ID: 32139151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
    Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
    Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.
    Ross DS; Devereaux KA; Jin C; Lin DY; Zhang Y; Marra A; Makker V; Weigelt B; Ellenson LH; Chui MH
    Mod Pathol; 2022 Jul; 35(7):962-971. PubMed ID: 34972830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
    Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG
    Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Landscape of Endometrial, Ovarian, and Cervical Cancers in Japan from the Database in the Center for Cancer Genomics and Advanced Therapeutics.
    Xi Q; Kage H; Ogawa M; Matsunaga A; Nishijima A; Sone K; Kawana K; Oda K
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; Zhang S; ; Lozy F; Sgroi DC; Vidal Bel A; Matias-Guiu X; Broaddus RR; Lu KH; Levine DA; Mutch DG; Goodfellow PJ; Salvesen HB; Mullikin JC; Bell DW
    Cancer; 2017 Sep; 123(17):3261-3268. PubMed ID: 28485815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome.
    Wadee R; Grayson W
    Ann Diagn Pathol; 2019 Apr; 39():92-104. PubMed ID: 30798077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
    Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Hillman RT; Lin DI; Lawson B; Gershenson DM
    Gynecol Oncol; 2021 Sep; 162(3):728-734. PubMed ID: 34238613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
    Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
    JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.